Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Research analysts at Seaport Res Ptn cut their Q1 2025 earnings per share estimates for shares of Curaleaf in a research note issued on Wednesday, March 5th. Seaport Res Ptn analyst S. Randhawa now expects that the company will post earnings per share of ($0.07) for the quarter, down from their prior estimate of ($0.06). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Seaport Res Ptn also issued estimates for Curaleaf's Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.24) EPS.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.09. Curaleaf had a negative return on equity of 13.67% and a negative net margin of 14.82%. The company had revenue of $331.05 million for the quarter, compared to the consensus estimate of $331.87 million.
Curaleaf Stock Performance
CURLF traded down $0.02 during midday trading on Monday, reaching $0.99. The company's stock had a trading volume of 985,502 shares, compared to its average volume of 748,980. Curaleaf has a twelve month low of $0.88 and a twelve month high of $6.40. The stock has a market cap of $654.02 million, a P/E ratio of -3.41 and a beta of 0.57. The company has a fifty day simple moving average of $1.41 and a 200 day simple moving average of $2.13. The company has a current ratio of 1.11, a quick ratio of 0.51 and a debt-to-equity ratio of 0.85.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Articles
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
